London, UK; Brentwood, TN, US: 9 August 2007 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, announces that the following
6 monthly block listing return in respect of the Company's 6% unsecured
convertible loan notes has been lodged with the FSA today, in accordance
with Listing Rule 3.5.6.
